Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22947
Title: Effect of Panax Ginseng (G115) Capsules versus Placebo on Acute Exacerbations in Patients with Moderate to Very Severe COPD: A Randomized Controlled Trial.
Austin Authors: Chen, Yuanbin;Lin, Lin;Wu, Lei;Xu, Yinji;Shergis, Johannah L;Zhang, Anthony L;Wen, Zehuai;Worsnop, Christopher J ;Da Costa, Cliff;Thien, Frank;Xue, Charlie C
Affiliation: The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine and Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, People's Republic of China..
Institute of Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australia
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine and Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, People's Republic of China..
School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia
School of Science, RMIT University, Bundoora, Victoria, Australia
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine and Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, People's Republic of China
Department of Respiratory Medicine, Eastern Health, Victoria, Australia, and Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia
Issue Date: 27-Mar-2020
metadata.dc.date: 2020-03-27
Publication information: International journal of chronic obstructive pulmonary disease 2020; 15: 671-680
Abstract: Herbal medicines are commonly used by people with chronic obstructive pulmonary disease (COPD) but high quality randomized controlled trials are limited. This study evaluated the therapeutic value of ginseng capsules in reducing acute exacerbations and improving the quality of life in people with COPD. This randomized, double-blind and placebo-controlled trial assessed ginseng's effects on 200 patients with moderate to very severe COPD. Ginseng capsules (200 mg, twice per day) were compared to placebo over 24 weeks. Patients were followed up for a further 24 weeks after the treatment period. The primary outcome measure was acute COPD exacerbation rate over 12 months. Secondary outcome measures were health-related quality of life, including the St George's Respiratory Questionnaire (SGRQ), COPD Assessment Test (CAT) and the Short Form 36 Health Survey (SF-36). We also assessed lung function, walking distance and use of relief medication. Baseline characteristics were balanced between groups. The rate of COPD exacerbations was not statistically significant between groups after 1 year (62 participants in the ginseng group and 63 in the placebo group). Secondary outcome measures showed improvements after ginseng and placebo but results were not clinically significant. The incidence of adverse events in the two groups was similar and events were unrelated to the intervention. Compared with placebo, ginseng did not reduce the rate of acute COPD exacerbations over 12 months. It was safe and well tolerated by people with moderate to very severe COPD.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22947
DOI: 10.2147/COPD.S236425
ORCID: 0000-0003-1169-5904
0000-0002-9147-5516
0000-0002-1840-1617
0000-0002-0968-9380
0000-0002-1797-2047
0000-0003-0925-6566
PubMed URL: 32273696
Type: Journal Article
Subjects: COPD
exacerbation
ginseng
quality of life
randomized controlled trial
Appears in Collections:Journal articles

Show full item record

Page view(s)

2
checked on Dec 1, 2020

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.